Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

Australia

Austria

Belgium

Brazil *

Canada

China *

Denmark

Finland

France

Germany

Hong Kong *

India *

Ireland

Italy

Japan *

Luxembourg

Mexico *

Netherlands

Norway

Philippines *

Republic of Korea *

Singapore *

Spain

Sweden

Switzerland

Thailand *

United Kingdom

United States

HTRF EPIgeneous Binding Domain Discovery Kit, 500 Assay Points

The Discovery assay enables to determine which of the EPIgeneous binding domain kits must be used for a given epîgenetic binding domain-histone interaction.

View product information

Feature	Specification
Application	Biochemical Enzymatic Assay
Sample Volume	120 µL

Request More Information

The Discovery assay enables to determine which of the EPIgeneous binding domain kits must be used for a given epîgenetic binding domain-histone interaction.

View product information

Product Variant

Part #:

62BDDPEG

List Price

USD 1,064.35

Your online price:

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption, and disposal requirements under European REACH regulations (EC 1907/2006).

Product information

Overview

The EPIgeneous Binding Domain kit series provides a simple biochemical approach to study epigenetic reader interactions with modified histones. The three kits, A, B and C, have been validated on 28 different bromo-, chromo- and tudordomains. All kits are based on a GST-tagged binding domain /biotin-coupled Histone peptide format, and can be run using the same add-and-read single plate protocol. Whenever a given domain is not part of the list of validated interactions, the Discovery Binding Domain kit enables researchers to profile which of the A, B or C kits is the best assay solution.

Specifications

Other Specifications

Application	Biochemical Enzymatic Assay
Brand	EPIgeneous
Detection Modality	HTRF
Product Group	Kit
Sample Volume	120 µL
Shipping Conditions	Shipped in Dry Ice
Target Class	Epigenetics
Technology	TR-FRET
Therapeutic Area	Metabolism/Diabetes Neuroscience Oncology & Inflammation
Unit Size	500 assay points

Video gallery

How it works

Assay principle

In EPIgeneous Binding Domain kits, the GST-tagged reader domain protein binding to the biotinylated peptide substrate is detected by a conjugate mix: anti-GST Eu or Tb cryptate-labeled antibody conjugate (donor), and streptavidin conjugated to either d2 or XL665 (acceptor). The interaction of the reader domain with the substrate brings the donor and acceptor dyes into close proximity, and allows FRET to occur upon light excitation. The specific signal at 665 nm is inhibited when a specific compound prevents the reader domain protein from binding to its substrate.

Assay validation

Validated binding domains

Three kits (A, B and C) have already been validated and fully optimized on a selection of 28 key binding domains. For non-validated reader domains, a fourth one, the Discovery Kit, enables researchers to profile which of the A, B or C kits is the best assay solution.

epigenetics-tab3-valid-binding-domains-62bddpeg

BINDING DOMAIN KIT A	BINDING DOMAIN KIT B	BINDING DOMAIN KIT C
BRD2(1)	CECR2	BRD4(1/2)
BRD3(1)	FALZ (BPTF)	ATAD2A
BRD4(1)	BRD2(2)	ATAD2B
CBX 1	BRD2(1/2)	BRD9
	BRD3(2)	SMARCA4 (BRG1)
	BRD3(1/2)	BAZ2B
	BRD4(2)
	BRDT(1)
	BRDT(1/2)
	CREBBP
	BRD1
	BRPF3
	TAF1L(2)
	TAF1L(1/2)
	TAF1(2)
	TAF1(1/2)
	L3MBTL1
	UHRF1